Acer Therapeutics Inc, a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes three clinical-stage candidates: EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; and ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders, maple syrup urine disease, and osanetant for the treatment of various neuroendocrine disorders. Read More…

When is Acer Therapeutics' next earnings date?

What price target have analysts set for ACER?

5 Wall Street analysts have issued 1-year price targets for Acer Therapeutics' stock. Their forecasts range from $9.00 to $48.00. On average, they expect Acer Therapeutics' share price to reach $31.00 in the next twelve months. This suggests a possible upside of 848.0% from the stock's current price. View Analyst Price Targets for Acer Therapeutics.

What is the consensus analysts' recommendation for Acer Therapeutics?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Acer Therapeutics in the last year. There are currently 3 hold ratings and 2 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Acer Therapeutics.

Has Acer Therapeutics been receiving favorable news coverage?

Media coverage about ACER stock has trended somewhat positive recently, InfoTrie reports. The research group scores the sentiment of media coverage by reviewing more than six thousand blog and news sources in real time. The firm ranks coverage of publicly-traded companies on a scale of negative five to five, with scores nearest to five being the most favorable. Acer Therapeutics earned a media sentiment score of 0.9 on InfoTrie's scale. They also gave news coverage about the biopharmaceutical company a news buzz of 1.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the near future. View News Stories for Acer Therapeutics.

Which major investors are buying Acer Therapeutics stock?

ACER stock was acquired by a variety of institutional investors in the last quarter, including BlackRock Inc., Wedbush Securities Inc., Citadel Advisors LLC, Vanguard Group Inc., Jane Street Group LLC, Charles Schwab Investment Management Inc., Bank of New York Mellon Corp and Northern Trust Corp. Company insiders that have bought Acer Therapeutics stock in the last two years include Life Science Ventures Vii Tvm and Steve Aselage. View Insider Buying and Selling for Acer Therapeutics.

How do I buy shares of Acer Therapeutics?

Shares of ACER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Acer Therapeutics' stock price today?

One share of ACER stock can currently be purchased for approximately $3.27.

How big of a company is Acer Therapeutics?

Acer Therapeutics has a market capitalization of $33.03 million and generates $2.90 million in revenue each year. The biopharmaceutical company earns $-21,280,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Acer Therapeutics employs 23 workers across the globe.View Additional Information About Acer Therapeutics.

MarketBeat Community Rating for Acer Therapeutics (NASDAQ ACER)

MarketBeat's community ratings are surveys of what our community members think about Acer Therapeutics and other stocks. Vote "Outperform" if you believe ACER will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ACER will underperform the S&P 500 over the long term. You may vote once every thirty days.